Every year, around 300,000 children are born worldwide with β-thalassaemia, a type of hereditary anaemia that, that it presents asymptomatically in most cases, can become fatal. With around 250 million people affected, β-thalassaemia is estimated to be the most common hereditary disease at global level. This β-thalassaemia, moreover, is also known as “Mediterranean anaemia”, since it is most common in the Mediterranean basin.
β-Thalassaemia treatment. Now, researchers from Yale University in New Haven (United States) have discovered a new β-thalassaemia treatment using genetic engineering technique to cure it; the method uses “pieces” of synthetic DNA that are then administered intravenously, and can correct the mutations that cause beta β-thalassaemia.(See HERE).